Livzon Pharmaceutical (HKG:1513, SHE:000513) agreed to acquire around 3.5% shares in Livzon Group Xinbeijiang Pharmaceutical from Zhuhai Zhong Hui Yuan Investment Partnership for roughly 106.7 million yuan.
Following completion, the company's direct shareholding in the target will increase to 90.64% from 87.14% previously, according to a Friday Hong Kong bourse filing.
Livzon Group Xinbeijiang Pharmaceutical engages mainly in the production of APIs and intermediates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.